<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006231</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068155</org_study_id>
    <secondary_id>CRC-BOC-L52</secondary_id>
    <secondary_id>EU-20033</secondary_id>
    <nct_id>NCT00006231</nct_id>
  </id_info>
  <brief_title>Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma</brief_title>
  <official_title>A Randomized Study to Assess Whether Radiotherapy Prevents Skin Lumps at Sites Where Needles or Tubes Have Been Inserted in Patients With Malignant Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet&#xD;
      known if radiation therapy is effective in preventing metastatic cancer following surgery.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to determine the effectiveness of radiation therapy in&#xD;
      preventing metastatic cancer in patients who have undergone diagnostic procedures to identify&#xD;
      malignant mesothelioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of radiotherapy in the prevention of metastatic skin nodules or&#xD;
           tumor seeding following invasive diagnostic procedures, such as chest drain insertion,&#xD;
           pleural aspiration, pleural biopsy, and thoracoscopy, in patients with malignant&#xD;
           mesothelioma.&#xD;
&#xD;
        -  Determine whether the nodules that develop after radiotherapy are symptomatic in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the quality of life of patients treated with radiotherapy vs standard care&#xD;
           alone.&#xD;
&#xD;
      OUTLINE: This is a randomized study.&#xD;
&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive radiotherapy on 3 consecutive days beginning within 3 weeks&#xD;
           after chest drain insertion, pleural aspiration, pleural biopsy, or thoracoscopy and&#xD;
           once the wounds have healed.&#xD;
&#xD;
        -  Arm II: Patients receive standard supportive care alone. Quality of life is assessed at&#xD;
           baseline, and then at 1, 2, 4, 6, 9, and 12 months.&#xD;
&#xD;
      Patients are followed at 1, 2, 4, 6, 9, and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 patients (22 per arm) will be accrued for this study within&#xD;
      2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1998</start_date>
  <completion_date type="Actual">December 2002</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of metastatic skin nodules</measure>
  </primary_outcome>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Malignant Mesothelioma</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>standard follow-up care</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven malignant pleural mesothelioma by chest drain insertion, pleural&#xD;
             aspiration, pleural biopsy, and/or thoracoscopy within the past 3 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior systemic chemotherapy for malignant mesothelioma&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior local radiotherapy for malignant mesothelioma&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other invasive procedures to the same chest site during and for 1 year after study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noelle O'Rourke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gartnavel General Hospitall</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stobhill General Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G21 3UW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>O'Rourke N, Paul J, Hill J: Radiotherapy to mesothelioma drain sites may not be worthwhile: interim report of a randomized study. Lung Cancer 29(1 Suppl 1): A-568, 168, 2000.</citation>
  </results_reference>
  <verification_date>October 2000</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>localized malignant mesothelioma</keyword>
  <keyword>advanced malignant mesothelioma</keyword>
  <keyword>perioperative/postoperative complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

